Marina Biotech, Inc.

Other

Biomics Biotechnologies, Co., Ltd.

Mdrna, Inc.

Agave Pharma, Incorporated

Cui, Kunyuan

Sweedler, David

Liang, Dong

Kunyuan Cui

Dong Liang

Michael E Houston, Jr

Lishan Chen

Benjamin H Dutzar

David Sweedler

Yuching Chen

Mohammad Ahmadian

Shu-Chih Chen

Sasha J Mayer

Shu-Chih Chen Quay

Long interfering nucleic acid (iNA) duplexes, which are at least 30 nucleotides in length, which have at least one nick or nucleotide gap in the antisense or the sense strands or in both the sense and antisense strands. These long iNA duplexes do not induce an interferon response when transfected into mammalian cells. The antisense strands can target two separate mRNAs or two segments of one mRNA.

Long interfering nucleic acid duplexes targeting multiple RNA targets

What is described are macrocyclic compounds formed by reaction of a cyclic compound, which contains an amine, with an epoxide. The macrocyclic compound has the following structure: When substituents R and R' that are hydrophobic substituents, the macrocyclic compound functions as a lipid and is compatible with lipid systems, including liposomes and lipid particles. When present in certain lipid systems, the macrocyclic compound enhances the ability of the lipid system to facilitate delivery of therapeutic molecules to target cells in a mammalian subject.

Lipomacrocycles and uses thereof

This disclosure provides compositions consisting of solid mixture of cationic lipids and a polynucleotide, wherein the cationic lipid molecules form a water-insoluble ionic complex with the polynucleotide. What is also described is an anhydrous mixture of the cationic lipids and the polynucleotide solubilized in an organic or polar aprotic solvent. The anhydrous compositions are useful in preparing therapeutic formulations and in the diagnosis and treatment of diseases and conditions. The compositions are useful for delivery of agents such as nucleic acid therapeutics to cells, tissues, organs, and subjects.

Compositions comprising cationic amphiphiles and colipids for delivering therapeutic molecules

A delivery-enhancing peptide comprising the amino acid sequence of SEQ ID NO:11 or salt thereof. This invention is directed towards methods and compositions to administer a double-stranded ribonucleic acid to a mammal so as to effectuate transfection of the double-stranded RNA into a desired tissue of the mammal.

Methods and compositions for enhancing delivery of double-stranded RNA or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells

Polynucleotide delivery-enhancing polypeptides are admixed or complexed with, or conjugated to, nucleic acids for enhancing delivery the nucleic acids into cells. The transported nucleic acids are active in target cells as small inhibitory nucleic acids (siNAs) that modulate expression of target genes, mediated at least in part by RNA interference (RNAi). The siNA/polypeptide compositions and methods of the invention provide effective tools to modulate gene expression and alter phenotype in mammalian cells, including by altering phenotype in a manner that eliminates disease symptoms or alters disease potential in targeted cells or subject individuals to which the siNA/polypeptide compositions are administered.

Compositions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells

The use of antagonists to JAM-1 Claudin-4 and occludin to open tight junctions. The antagonists include, by way of example antibodies and antibody fragments that bind to the proteins and small interfering nucleic acids that downregulate the mRNA encoding the proteins.

Method for opening tight junctions

Growing community of inventors

Bothell, WA, United States of America

Kunyuan Cui